Web Exclusives

The pharmaceutical industry has a head-start on heavyweight compliance and legacy product transparency requirements but do medical device manufacturers bring new advantage from an engineering mindset?

Gilead’s Hilary Hutton-Squire on industry, innovation, and the NICE Methods Review

Industry consolidation continues apace, harming competition and reducing choice. Alan White warns that customers now need to be more discerning when assessing suppliers’ relative value.

Geoff Twist, managing director for Roche Diagnostics UK and Ireland, on working towards cancer treatment that’s fit for the future

To mark World Cancer Day, PharmaTimes talks to Janssen’s Biljana Naumovic about the current landscape in oncology

Momentum and vision around IDMP must be maintained in 2020 if standardised medicinal product data is to be of tangible real-world benefit

Why companies need to upskill sales reps so they can thrive in this new data-driven world

How artificial intelligence (AI) is changing the pharma and biotech industries

Comparing safety in pharmaceutical advertising

Cassie Walker considers the role of Certainty Based Marking in developing an effective training strategy for pharma employees

Most biopharma marketing executives say they don’t know what clients want – it’s time to change that

Duncan McKay considers whether the UK picked a winner in cell and gene therapy

Susan Dillon and Richard Baderin say taking the time to fully assess a portfolio can reap highly measurable rewards for life sciences companies, and offer advice on the key areas to focus on for both marketed and non-marketed brands.

Jim O’Donoghue considers how pharma can build on digital foundations to focus on outcomes